FDx Advisors Inc. Has $231,000 Stock Position in Sanofi (NASDAQ:SNY)

FDx Advisors Inc. lowered its position in shares of Sanofi (NASDAQ:SNY) by 11.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,792 shares of the company’s stock after selling 593 shares during the quarter. FDx Advisors Inc.’s holdings in Sanofi were worth $231,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Synergy Asset Management LLC purchased a new position in Sanofi during the 4th quarter worth approximately $25,000. McClarren Financial Advisors Inc. grew its holdings in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after buying an additional 543 shares in the last quarter. Concord Wealth Partners raised its position in Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after buying an additional 363 shares during the period. Fortitude Family Office LLC lifted its stake in Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares in the last quarter. Finally, Sunbelt Securities Inc. boosted its position in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Stock Performance

Shares of SNY stock opened at $54.46 on Friday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The stock’s 50-day moving average is $50.95 and its two-hundred day moving average is $52.52. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm has a market cap of $138.21 billion, a P/E ratio of 21.87, a PEG ratio of 1.00 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.